SERA PROGNOSTICS, INC. (SERA) Quick Ratio
- Quick ratio · latest quarter: Value 1.91×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.91× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $46.45M ÷ $24.36M ≈ 1.91× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 46.45M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 24.36M USD | Liabilities, Current |
| Cash and equivalents | 4.40M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 42.05M USD | Marketable Securities, Current |
| Customer receivables | 10.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $46.45M | $24.36M | $4.40M | $42.05M | $10.00K | (m) | 1.91× |
| 2026-03-31 | $47.41M | $23.42M | $4.17M | $43.23M | $11.00K | (m) | 2.02× |
| 2025-12-31 | $39.21M | $24.19M | $3.94M | $35.26M | $12.00K | (m) | 1.62× |
| 2025-09-30 | $43.32M | $23.50M | $4.08M | $39.22M | $14.00K | (m) | 1.84× |
| 2025-06-30 | $40.18M | $23.60M | $5.02M | $35.14M | $17.00K | (m) | 1.70× |
| 2025-03-31 | $46.22M | $23.40M | $5.23M | $40.97M | $25.00K | (m) | 1.98× |
| 2024-12-31 | $46.27M | $24.77M | $4.04M | $42.19M | $34.00K | (m) | 1.87× |
| 2024-09-30 | $49.83M | $24.18M | $2.68M | $47.07M | $79.00K | (m) | 2.06× |
| 2024-06-30 | $51.04M | $24.76M | $4.66M | $46.28M | $101.00K | (m) | 2.06× |
| 2024-03-31 | $53.09M | $24.57M | $4.24M | $48.73M | $117.00K | (m) | 2.16× |
| 2023-12-31 | $49.24M | $24.44M | $3.88M | $45.20M | $160.00K | (m) | 2.01× |
| 2023-09-30 | $46.27M | $13.54M | $9.65M | $36.46M | $155.00K | (m) | 3.42× |
| 2023-06-30 | $63.98M | $14.18M | $32.28M | $31.54M | $163.00K | (m) | 4.51× |
| 2023-03-31 | $70.91M | $13.80M | $27.20M | $43.59M | $120.00K | (m) | 5.14× |
| 2022-12-31 | $82.82M | $15.54M | $29.88M | $52.83M | $113.00K | (m) | 5.33× |
| 2022-09-30 | $88.89M | $8.67M | $38.81M | $49.97M | $107.00K | (m) | 10.26× |
| 2022-06-30 | $106.98M | $7.30M | $53.89M | $53.02M | $73.00K | (m) | 14.65× |
| 2022-03-31 | $107.59M | $6.94M | $64.08M | $43.47M | $39.00K | (m) | 15.49× |
| 2021-12-31 | $105.14M | $8.41M | $58.93M | $46.18M | $27.00K | (m) | 12.50× |
| 2021-09-30 | $120.01M | $3.54M | $82.48M | $37.50M | $35.00K | (m) | 33.87× |
| 2021-06-30 | (m) | $3.23M | $90.85M | (m) | $14.00K | (m) | (m) |
| 2020-12-31 | (m) | $11.24M | $13.53M | (m) | $2.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |